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ABSTRACT 
 
 
 This thesis describes the development of libraries inspired by the natural product 
sparteine. Multi-gram synthesis of important intermediate representing sparteine core has been 
carried out. A scalable process has been developed based on the previously reported total 
synthesis of (+)-sparteine from Aubé’s group. Libraries were produced via parallel synthesis and 
submitted to NIH Molecular Libraries-Small Molecule Repository for biological screening. 
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Chapter 1 
Introduction 
 Natural products in drug discovery. Natural products have been used to counter human 
health problems since thousands of years. The medicinal effects of many natural products like 
cinchona and digitalis were recognized much before the isolation of their active constituents.  
Nothing was known about the chemistry of the plants and the applications were based on 
empirical observation. The traditional and folklore remedies in various cultures were based on 
using crude plant extracts and are recorded in ancient writings of different cultures (De Materia 
Medica, Chinese Materia Medica and Indian Ayurveda).1 
 Development of better purification techniques made it possible to isolate the pure 
biologically active components of natural products. Analytical techniques also made it possible 
to quantify the bioactivities of these compounds. Health care systems eventually matured to use 
the pure natural products as clinically validated drugs (e.g. erythromycin, chlortetracyclline, 
quinine, reserpine) (Figure 1). Discoveries of anti-cancer drug paclitaxel2 and cholesterol 
lowering drug mevinolin (lovastatin)3 are considered very significant achievements along these 
lines (Figure 1). Medicinally important substances from all kind of natural sources, animals (e.g. 
exetanide and ziconotide), plants (e.g. elliptinium, glantamine and huperzine) and microbes (e.g. 
daptomycin) have been derived since then.4 
  The advent of X-ray crystallography and later highly advanced techniques like NMR 
spectroscopy, have often led to the determination of the intricate structures of natural products. 
These structures provided an intriguing challenge to the organic chemist who was testing his 
scientific skills and hypothesis by constructing simple organic molecules. Since then, natural 
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product synthesis has come a long way. The field of organic synthesis, which started with the 
synthesis of urea, has achieved the milestones of synthesizing natural products like strychnine5 in  
 
Figure 1. Natural product drugs 
 
O
O
OH
HO OH
O
O
OHO
N
O
O
OH
OH
OOH
H H N
OH
H3C CH3
O
NH2
HO
Cl OH
O
N
O
NHO
O
NH
HO O
O
O
OAc
O
HO
CH3OH
O
Ac
O
O
HO
OO
OHO
N
H
N
H
H3COOC
OH
H
OCH3
H3CO
O
OCH3
OCH3
OCH3
erythromycin chlortetracyclline
reserpine quinine
taxol mevinolin
H
O
	   3 
the mid-1950s and molecules like taxol6 and calicheamicin7 in recent years. The knowledge and 
skills gained along the way had significant impact on the area of drug discovery. Scalable 
synthetic routes were developed for the natural product drugs, which were not available in 
required quantities directly from natural resources or via fermentation processes. Two very 
noticeable achievements in this direction were the development of a scalable synthetic route to 
thienamycin8 in 1981 and discodermolide9 in recent years. Semi-synthesis of natural products 
provided drugs with improved pharmacokinetic and biological profile (e.g. clarithromycin, 
azithromycin, tigecycline, naloxone) (Figure 2).  
 
Figure 2. Semi-synthetic analogues of natural products 
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 An increasing understanding of molecular biology and the mapping of human genome 
revealed various new biological targets of both fundamental and therapeutic interest.10 
Researchers in both academics and industry began to explore therapeutic potential of newly 
revealed biological targets by developing libraries of small molecules for biological screening. 
With an aim of quickly building larger diverse libraries, the attention of the pharmaceutical 
industry moved away from natural products, which are often challenging to purify, structurally 
complex and available in only small quantities. The development of combinatorial chemistry 
offered the prospect of rapidly generating simpler, more drug-like screening libraries of wide 
chemical diversity. However the majority of the libraries examined was ineffective and provided 
disappointingly low hit rates.11 This outcome suggested that random sampling of chemical space 
might not be an effective solution to target complex biological targets.  Early libraries were 
generally designed on the basis of chemical accessibility and maximum achievable size. 
Theoretical calculations show that a complete set of possible small molecules is on the order of 
1030 – 10200.12 However, considering that at the molecular level biological systems work under 
strict solubility and structural constraints, only a small portion of this bewildering number may 
be relevant to biology. It has been a difficult but important question to answer that which regions 
of chemical space should be targeted to probe biology.  
 Natural product based libraries It is possible that many unsuccessful libraries 
underrepresented most of the natural product and metabolite scaffolds.13 Hence, unmet 
expectations from completely synthetic libraries, and the historical role of natural products in 
human therapeutics, prompted a renewed interest in natural products as a source of chemical 
diversity and lead generation. Since small molecule natural products are biosynthesized under 
enzymatic control, these may have structurally evolved to interact with conserved protein 
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domains.14 Hence compounds based on natural product scaffolds may be biologically relevant. 
However, the evolutionary reason behind the production of natural products is not therapeutic so 
these compounds may not have the optimal features needed for a drug candidate and must 
undergo additional structural modifications.15 Recently, libraries based on underrepresented 
scaffolds and natural products have led to several successes in identifying novel chemical probes 
for various biological targets.16 For example, Schreiber and coworkers discovered robotnikinin 
(Figure 3), a 12-membered macrocycle, an inhibitor of hedgehog signal transduction pathway, 
following screens of a 2070-membered macrocycle libraries based on natural product scaffolds.17 
Spring and coworkers identified gemmacin (Figure 3), a new antibacterial agent from a 242-
membered library of 18 natural product-like scaffolds.18 
Figure 3. Examples of leads based on natural product scaffolds 
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scaffold depends upon the reactive functional groups of the natural product and stereochemical 
diversity (e.g., access to the opposite enantiomer) is generally not available. The library is 
developed by derivatization of the existing scaffold. The androphoglide-derived library shown in 
Scheme 1 is illustrative.20 Andrographolide 1 was transformed into intermediate 2 via a six-step 
synthetic sequence in 39% overall yield. Compound 2 was treated with thiourea in pyridine 
resulting in a fused aminothiazole ring system, which was subjected to N-acylation with fifteen 
different acid chlorides to produce the scaffolds 3. Alkaline hydrolysis of 3 led to dihydroxy 
carboxylic acids, which on activation with Mukaiyama reagent, followed by treatment with a set 
of twenty-four amines generated the 360-compound library 4.  
 
Scheme 1. Synthesis of androphoglide-derived library 
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 Though the above-mentioned approach gives an advantage of quickly launching a 
multidimensional diversity campaign, it is limited by the following factors,  
1. Availability of significant amounts of pure natural product, which is often problematic 
especially for newly-discovered natural products. 
2. Multifunctional natural products present a challenge of chemoselectivity, so introducing 
desired modifications may not be practical (e.g., polyhydroxy natural products like quinic 
acid) (Figure 4). 
3. Absence of reactive functional groups may also limit the scope of library synthesis (e.g., 
sparteine) (Figure 4). 
4. The scope of introducing new stereocenters is limited by the inherent geometry and steric 
environment of the natural product core. 
5. Unstable natural products under certain reaction conditions lead to complicated mixtures 
of products.    
Figure 4. Examples of multi-functional and non-functional natural products    
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desired future modifications earlier in the synthesis from an advanced intermediate B and can 
omit potentially troublesome moieties that might interfere with proposed biological applications 
or which could be problematic for the final molecular modifications. It provides a major 
advantage by allowing access of analogues with higher structural complexity (analogue D) or 
lower level of molecular complexity (analog E) than the natural product scaffold (C) under 
consideration. This, in turn, allows chemists to explore a wider chemical space not available by 
starting with the natural product itself.  
 
Figure 5. Danishefsky’s diverted total synthesis (DTS) 
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analogues were highly potent against different cancer cell lines and are currently under 
preclinical or clinical evaluation. 
 
Figure 6. Diverted total synthesis of epothilones  
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sequence provided straightforward access to the tricyclic core of the stemona alkaloids (Scheme 
2). Systematic chemical manipulation combined with parallel synthesis produced 104 analogs for 
41-panel GPCR screening. This library campaign ultimately resulted in the identification of a 
highly potent class of sigma ligands.   
 
Figure 7. Stenine alkaloids 
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Scheme 2. Synthesis of stemona alkaloid inspired analogues 
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 The outcome of the stenine library provides recent evidence that libraries based on 
natural products having rich biological profiles may provide potent ligands or probes for 
biological systems. Inspired by the results of the stenine library, we envisioned that the natural 
product sparteine would be an interesting starting point for library development for the following 
reasons: (1) Sparteine has a rich biological profile and (2) an effective route to the sparteine 
scaffold based on a previously reported total synthesis from this group. 
  
Sparteine 
Introduction: Sparteine is a lupidine alkaloid, isolated from Cytisus scoparius (scotch broom) in 
1851 by Stenhouse.27 It exists as four isomers as depicted in Figure 8. It has also been identified in 
many papilionaceous plants. However,  (+)-sparteine is much less abundant.  
 
Figure 8. Naturally occurring sparteine isomers 
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 Biological activity of (−)-sparteine and other lupine alkaloids. The alkaloid (−)-sparteine 
has a rich biological profile that includes nicotinic ester antagonism,28 application as a profiling 
agent in metabolic studies,29 and clinical use as an antiarrythmic30 agent. Other members of the 
lupanine class of alkaloids (Figure 9) also exhibit activity against muscarinic and nicotinic 
receptors. Cytisine (Tabex®) and vereniciline (Chantix®, a drug designed based on cytisine) 
have been used in Europe for smoking cessation due to their agonist activity against α4/32-
nAChR.31 
 
Figure 9. Other lupanine alkaloids structurally related to sparteine 
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 Sparteine syntheses. To the best of our knowledge, four racemic syntheses of sparteine 
have been reported to date. In 1950, Leonard and Byler accomplished the first racemic synthesis 
of sparteine using reductive alkylation of 2,4-di (α-pyridyl)-glutarate as the key step (Scheme 
3).32 The synthesis led to a 5:1 mixture of dl-sparteine and dl-α-isosparteine with a combined 
yield of 31%.  
 
Scheme 3. Leonard and Beyler’s synthesis of dl-sparteine 
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Scheme 4. Van Tamelen and Foltz’s synthesis of dl-sparteine 
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 Bohlman and coworkers accomplished the synthesis of dl-sparteine in 0.6% overall yield 
via intramolecular cyclization of an enamine-imminium ion intermediate (Scheme 5).34 
 
Scheme 5. Bohlmann’s synthesis of dl-sparteine 
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Scheme 6. Otamasu’s synthesis of dl-8-oxosparteine 
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quantities from natural products. There was no total synthesis of (+)-sparteine [or (−)-sparteine] 
reported before 2002.  
 Two reports of the asymmetric synthesis of sparteine have appeared between 2002 and 
the present. In 2004, O’Brien reported an asymmetric synthesis of (−)-sparteine from ethyl-7-
iodohept-2-enoate (Scheme 7).37 The key feature of the route is a Michael reaction between an 
amino ester-derived enolate and a α,β-unsaturated amino ester.  
 
Scheme 7. O’Brien’s asymmetric synthesis of (−)-sparteine 
 
 
  
 
 
 
 
N
Ph
H
O OEt
NR1
H
O OEt
H
R2N
H
O
OEt
H
N
Ph
H
O OEt
N
N
H
H
N
N
H
O
O
H
+
36% (over 
  2 steps)
Pd(OH)2/C, NH4+HCO2-
EtOH, reflux, 14 h
3 : 2
R1 = (S)-!-methylbenzyl
R2 = (R)-!-methylbenzyl
(")-sparteine
N
Ph
H
O OEt
LDA, "78 #C+
LiAlH4
88%
	   17 
 In 2002 Aubé and co-workers reported the first asymmetric synthesis of (+)-sparteine in 
15 steps and 15.7% overall yield from optically pure (1S, 4S)-2,5-norbornadione.38 The total 
synthesis was accomplished from 2,5-norbornadione via two ring-expansion reactions, one 
involving an intramolecular Schmidt reaction and other one using a novel variant of the photo-
Beckmann rearrangement as key steps (Scheme 8). The required chiral diketone was prepared 
via a three-step reaction sequence involving a chiral hydrosilation method developed by Hiyashi 
as a key step.39 As either of the enantiomers of 2,5-norbornadione can be prepared by this 
method using the opposite ligand, both enantiomers of sparteine can be prepared in optically 
pure form by using the following synthetic route.  
 
Scheme 8. Aubé’s asymmetric synthesis of (+)-sparteine 
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 In summary, for many years natural products have been a source of inspiration, both for 
discovering new drugs and for the fundamental advancement of chemistry and biology.  Recent 
developments indicate that small molecule libraries based on natural product scaffolds have 
tremendous potential for finding new probes for biological systems.  
 Inspired by the success of the stenine project and based on the rich biological profile of 
sparteine, we hypothesize that libraries inspired by the sparteine scaffold may be of considerable 
interest for biological exploration. The present work is focused on developing small libraries 
based on the sparteine scaffold and will be discussed in detail in the following chapter. 
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Chapter 2 
Results and Discussion          
 The work reported in this thesis is focused on developing a collection of compounds 
based on the sparteine scaffold.  Though scalable routes to racemic or asymmetric sparteine are 
available, it would be less desirable to launch a library directly from sparteine as starting point 
because of two reasons: (1) the absence of reactive functional groups and (2) even if one 
introduces the reactive groups, the scope of diversity will be very limited and so will be the 
probability of finding small molecules with novel biological properties.  Based on analysis of the 
previously reported synthesis by Wendt and Smith from this group, we envisioned that by careful 
chemical manipulations of the advanced intermediates 11 and 15 as depicted in Scheme 9, it 
would be possible to gain access to the scaffolds 22a - g related to the sparteine core.  
 
Scheme 9. Synthetic plan for the synthesis of scaffolds  
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 The aim of this work was to develop a 120-compound library for biological screening 
based on the above-proposed plan. From the strategic point, in this part of the work we have 
targeted racemic compound library. Depending upon the biological results of these compounds, 
focused enantio-pure libraries can also be generated using above methodology starting from the 
optically pure 2, 5-norbornadione. We have generated a library of 120 compounds following the 
racemic synthesis in following three phases, 
1. Scale-up of the intermediate 15  
2. Gram scale synthesis of scaffolds 22d-g 
3. Development of library via parallel synthesis 
                   
 Racemic synthesis of the C2-symmetric diketone 8 (Scheme 10). The racemic 
synthesis of lactam 15 can be accomplished in 9 steps from norbornadiene as reported by Smith 
and Wendt. We have introduced a few modifications to the existing route for large-scale 
synthesis and will be discussed as we progress in this chapter. The racemic synthesis of diketone 
8 was accomplished from commercially available 2, 5-norbornadiene via a method reported by 
Hawkins and coworkers. 40 Addition of 5 equivalents of formic acid to the diene under refluxing 
conditions gave the trans-diformate 7 in excellent yield after purification by vacuum distillation. 
Hydrolysis of the diformate and oxidation of the resulting diol happened under Jones oxidation 
conditions resulting in 18-22 % of the corresponding diketone. However, this method was 
undesirable for the large-scale synthesis because of the following reasons: 
1. The large quantities of toxic chromium reagent are involved. 
2. Handling and work-up – requires large solvent extractions to extract the product from the 
dark slush formed in the Jones oxidation. 
	   21 
3. The poor overall yield is poor.  
To overcome above problems we tried a two-step protocol. Diformate 7 was hydrolyzed using 
aq. NaOH/THF. Our attempts to oxidize the resulting diol using bleach resulted in complex 
mixture of products. Swern oxidation did not provide optimum results because of the poor 
solubility of diol in dichloromethane. Further, below zero temperature conditions and greater 
dilutions required for the Swern oxidation makes it less attractive for the large-scale reactions. At 
this point we performed the diol oxidation using Taber’s modified conditions of the Albright-
Onodera oxidation.41 The reaction was carried out at 1M concentration at 0 °C. Though 
phosphorous pentoxide used in this reaction is highly hygroscopic however it does not require 
slow addition and can be quickly charged to the reaction. We have scaled-up >50 g of diketone 8 
using these conditions in 60% yield over two steps from 7.    
 
Scheme 10. Synthesis of racemic diketone 
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previously reported procedure in 80% yield.42 The aldol reaction of 9 with aldehyde 13 using 
LDA gave 10 in 91% yield as predominately one diastereomer with side chain presumably in the 
exo position resulting from the alkylation of the enolate from the less hindered exo face. 
Mesylation of alcohol 10 followed by refluxing in DBU/THF gave 11 as a mixture of E/Z 
olefins. The mixture 11 was submitted to hydrogenation conditions (10% Pd(OH)2, 10%  Pd-C, 
Ethanol, 60 psi H2) for 24 h. Hydrogenation of the olefin from the exo face and O-debenzylation 
gave 12 in  92% yield with the side chain in the endo position. It was interesting to note that the 
previously published yields in this synthesis proved highly reproducible in the current scale-up. 
 
Scheme 11. Alkylation of diketone 
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modified aza-Mitsunobu reaction conditions developed by Rollin.43 These conditions were 
employed to prevent the epimerization of the α−carbon to the carbonyl. However, using this 
method we could obtain 14 in only 57% yield during the current scale-up. Though the yield was 
still respectable, the loss of material was significant considering the scale and the number of 
steps involved in the synthesis of 12. To improve the yield, a two-step protocol was tested which 
involved conversion of alcohol 12 to the mesylate at 0 °C followed by SN2 displacement of the 
mesylate with an azide nucleophile. Conversion of alcohol to azide was achieved in 92% yield 
over two steps with no epimerization at the α-alkylated center. The intramolecular Schmidt 
reaction of azide 14 proceeded upon treatment with TiCl4 to obtain the required tricyclic lactam 
15 in 62% yield.   
Scheme 12. Synthesis of tricyclic lactam 
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Reductive amination of tricyclic ketolactam 15. The reductive amination of ketolactam 15 did 
not work under various conditions attempted (Table 1). The product was obtained only when a 
mixture of starting ketone and benzyl amine was stirred in neat TiCl4 followed by reduction with 
NaCNBH3/MeOH.44,45  The product was isolated in 70% yield (entry 4). However these 
conditions were not amenable for the development of library by parallel synthesis on Mini-
Block.    
 
Table 1. Reductive amination of ketone 
                                                           
	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  
	  
entry conditions result 
1 BnNH2/NaCNBH3/solventa S.M. 
  2 BnNH2/Na(OAc)3BH/solventa S.M. 
3 1. BnNH2/benzene/4Å MS/reflux 2. NaCNBH3 S.M. 
4 1.TiCl4 (neat) 2. NaCNBH3/MeOH 70% 
                                a. THF, 1,2-dichloroethane or Acetonitrile. 
These results are in coherence with the observations made by Wendt. He noticed the non-
reactivity of the alkylated form of this ketone under intramolecular Schmidt reaction conditions 
(Figure 10).46 It has also been noticed that even simple ketal protection of ketone 15 does not 
occur under standarad conditions.      
 
Figure 10. Reactivity of alkylated ketone 15 under Schmidt conditions 
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 Development of lactam 18a-x (Scheme 13). We envisioned that conversion of the 
ketone 15 to alcohol can be easily carried out in the presence of lactam and the resulting alcohol 
would provide opportunities for further modifications. To make our first library of lactams, 
ketone 15 was reduced to alcohol 16 using NaBH4/MeOH in 88% yield with complete 
diastereoselectivity (endo:exo  > 19:1). Stereochemistry of endo-fused ring as well as the endo-
C-4-hydroxy was confirmed by transforming alcohol 16 to p-bromobenzoate 16a and developing 
a single crystal X-ray (Figure 11). Alcohol 16 was converted to p-nitrophenylcarbonate 17 in 
95% yield on reacting with p-nitrophenylchloroformate in THF/Pyridine. We have chosen a set 
of diverse, alkyl (e.g., entries 4 and 5 in table 1), benzyl (entry 6), substituted benzyl (e.g., entries 
1and 2), heterocyclic (e.g., entries 3, 18 and 19) and heteroalkyl (e.g., entries 15 and 16) amines. 
Treatment of 17 with 5 eq. of these amines gave the carbamates 18a-x. A 24-compound library 
was produced with yield ranging from 38-100% and purities 84-100% (Table 2).  
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Scheme 13. Development of lactam-carbamate library 
                           
 
 
Figure 11. X-ray crystal structure of 16a   
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  Table 2. Lactam librarya 
entry alcohol Amine carbamate yield 
(%) 
purity 
 (%) 
1 16 4-fluorobenzyl amine 18a 100 100 
2 16 4-methoxybenzylamine 18b 100 100 
3 16 morpholine 18c 100 100 
4 16 n-butylamine 18d 100 100 
5 16 cyclohexylamine 18e 100 100 
6 16 benzylamine 18f 50 100 
7 16 4-bromobenzylamine 18g 65 99 
8 16 4-methylbenzyl amine 18h 90 98 
9 16 3, 5-dimethoxybenzyl 
amine 
18i 80 96 
10 16 methyl amine 18j 100 100 
11 16 n-propyl amine 18k 100 99 
12 16 isopropyl amine 18l 75 93 
13 16 ethanolamine 18m 100 99 
14 16 N, N-dimethylamino-1, 3-propanediamine 18n 100 99 
15 16 pyridine-3-yl-methanamine 18o 38 100 
16 16 2-(1H-indol-3-yl)ethanamine 18p 83 98 
17 16 piperidine 18q 85 99 
18 16 4-phenylpiperidine 18r 86 98 
19 16 4-methylpiperazine 18s 68 100 
20 16 4-phenylpiperazine 18t 100 95 
21 16 4-benzenesulphonylpiperazine 18u 100 96 
22 16 4-benzoylpiperazine 18v 73 91 
23 16 4-acetylpiperazine 18w 63 98 
24 16 4-(3’-thiophencarbonyl)-piperazine 18x 75 84 
a. HPLC methods of purification and analysis used for these compounds are provided in detail in the experimental section. 
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Development of amine library 20 (Scheme 14). Lactam 15 was refluxed with 10eq. of LiAlH4 
in THF leading to 19 in 80% yield. A set of 24 differently substituted phenyl isocyanates (e.g., 
entries 1, 3 and 13), benzyl isocyanate (entry 15), alkyl isocyanates (entry 18), cycloalkyl 
isocyanate (entry 17), arylalkyl isocyanates (e.g., entries 16 and 22) and heterocyclic isocyanates 
(entries 4 and 21) was selected. Amino alcohol 19 was reacted with isocyanates in acetonitrile 
under microwave conditions at 110 °C to produce 24 carbamates 20a-x in 40-100% yield and 
purities 33-100% (Table 2). Relative stereochemistry of the product was confirmed through X-
ray crystallography of compound 20i (Figure 12). 
 
Scheme 14. Development of microwave-assisted amine library 
              
 
Figure 12. X-ray crystal structure of 20i 
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Table 3. Amine librarya 
entry alcohol R carbamate yield 
(%) 
purity 
 (%) 
1 19 3, 5-dimethylphenyl 20a 100 87 
2 19 3, 4-dimethylphenyl 20b 100 99 
3 19 4-methoxybenzyl 20c 80 91 
4 19 2-thiophene 20d 92 97 
5 19 4-fluorophenyl 20e 82 100 
6 19 4-methylphenyl 20f 84 95 
7 19 2-trifluoromethylphenyl 20g 85 90 
8 19 3-trifluoromethylphenyl 20h 90 90 
9 19 2-methoxyphenyl 20i 65 99 
10 19 3-methylphenyl 20j 70 98 
11 19 4-bromomethylphenyl 20k 88 99 
12 19 3-bromomethylphenyl 20l 84 99 
13 19 4-cyanophenyl 20m 90 98 
14 19 4-(N,N-dimethylamino)phenyl 20n 40 33 
15 19 benzyl 20o 90 97 
16 19 4-ethylphenethyl 20p 92 92 
17 19 cyclohexyl 20q 84 92 
18 19 n-butyl 20r 80 100 
19 19 4-n-pentylphenyl 20s 88 82 
20 19 tert-butyl 20t 90 96 
21 19 3-indolyl 20u 73 41 
22 19 phenylpropyl 20v 93 98 
23 19 3-cyanophenyl 20w 92 100 
24 19 ethylbutanoate 20x 76 95 
a. HPLC methods of purification and analysis used for these compounds are provided in detail in the experimental section. 
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 Synthesis of scaffolds 23d-f (Scheme 15). Ketal protection of the ketone 15 did not 
occur under p-toluenesulfonicacid/ethyleneglycol/benzene conditions. The ketone 15 was 
protected using TMSCl/ethylene glycol to obtain ketal 21 in 70% yield.47 Compound 21 was 
treated with Grignard reagent under reflux and the resulting iminium salt was in situ reduced 
with sodium cyanoborohydride.48 The crude product obtained from this reaction was refluxed in 
HCl/acetone to give the unprotected ketone 22, which was found as a single diastereomer in 85-
90 % yield over two steps. The ketone 22 was converted to endo alcohol 23 in 85-88% yield 
using NaBH4/MeOH conditions. A set of 24 differently substituted phenyl, benzyl, alkyl, 
cycloalkyl, arylalkyl and heterocyclic isocyantes was selected. Alcohol 23 was transformed to 
carbamate 24 by reacting with isocyanate in THF in the presence of triethylamine at 50 °C. 
Using 24 different isocyanates for each of the scaffold (23d-f) a 72-compound carbamate library 
was produced by parallel synthesis on Mini-Block in 37-100% yield and purity 16-100% (Table 
3). The relative stereochemistry was confirmed through X-ray crystallography of compound 39e 
(Figure 13).   
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Scheme 15. Synthesis of scaffolds 
 
 
 
Figure 13. X-ray crystal structure of 39e 
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 In summary, we have produced a 120 compound library based on the sparteine scaffold. 
105 compounds passed the purity standards (> 90% by HPLC). Molecular properties of these 
compounds, HBA (number of hydrogen bond acceptors), HBD (number of hydrogen bond 
donors), number of rotatable bonds, PSA (polar surface area), and ClogP values have been 
calculated using SYBYL from TRIPOS (Table 5). For majority of the compounds, these values 
are within the range as defined by the Lipinski and Veber’s rules. The compounds have been 
submitted for biological screening to the NIH Molecular Libraries-Small Molecule Repository. 
During the course of this work, we have also developed an improved and Chromium-free route 
for the synthesis racemic diketone and demonstrated multigram synthesis of intermediate 15, 
which will facilitate to develop more libraries based on sparteine scaffold in future.   
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Table 4. Alkylated-amine librarya 
entry alcohol R1 R2 carbamate yield 
(%) 
purity 
(%) 
1 23d Me n-butyl 24d 37 23 
2 23d Me t-butyl 25d 58 18 
3 23d Me ethylbutanoate 26d 68 96 
4 23d Me 4-chlorobenzyl 27d 78 99 
5 23d Me 4-methylphenyl 28d 85 98 
6 23d Me 4-cyanophenyl 29d 88 99 
7 23d Me 3-cyanophenyl 30d 85 99 
8 23d Me 2-trifluoromethylphenyl 31d 88 91 
9 23d Me benzyl 32d 93 98 
10 23d Me 3-phenylpropyl 33d 90 97 
11 23d Me 2-(4-ethylphenyl)ethyl 34d 95 95 
12 23d Me 2-methoxyphenyl 35d 78 98 
13 23d Me 3-fluoroohenyl 36d 83 99 
14 23d Me 4-fluorophenyl 37d 86 99 
15 23d Me 3-bromophenyl 38d 63 40 
16 23d Me 4-bromophenyl 39d 92 90 
17 23d Me 2-chlorophenyl 40d 90 57 
18 23d Me 3-chlorophenyl 41d 90 99 
19 23d Me 4-chlorophenyl 42d 83 87 
20 23d Me 5-benzo[d][1,3]dioxole 43d 100 97 
21 23d Me 3-trifluorometylphenyl 44d 98 98 
22 23d Me 4-trifluoromethylphenyl 45d 96 98 
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23 23d Me 3, 5-dimethylphenyl 46d 100 85 
24 23d Me 4-(N, N-dimethylamino)phenyl 47d 92 52 
25 23e n-butyl n-butyl 24e 60 67 
26 23e n-butyl 4-ethylbutanoate 25e 59 67 
27 23e n-butyl 2-methylphenyl 26e 85 95 
28 23e n-butyl 4-methylphenyl 27e 88 92 
29 23e n-butyl 4-cyanophenyl 28e 90 98 
30 23e n-butyl 3-cyanophenyl 29e 87 98 
31 23e n-butyl phenyl 30e 90 95 
32 23e n-butyl benzyl 31e 100 100 
33 23e n-butyl 4-chlortobenzyl 32e 100 93 
34 23e n-butyl 3-phenylpropyl 33e 100 93 
35 23e n-butyl 2-(4-ethylphenyl)ethyl 34e 100 91 
36 23e n-butyl 2-methoxyphenyl 35e 98 96 
37 23e n-butyl 3-fluoroohenyl 36e 85 94 
38 23e n-butyl 4-fluorophenyl 37e 78 94 
39 23e n-butyl 3-bromophenyl 38e 90 67 
40 23e n-butyl 4-bromophenyl 39e 92 93 
41 23e n-butyl 2-chlorophenyl 40e 78 85 
42 23e n-butyl 3-chlorophenyl 41e 88 92 
43 23e n-butyl 4-chlorophenyl 42e 87 95 
44 23e n-butyl 5-benzo[d][1,3]dioxole 43e 98 99 
45 23e n-butyl 3-trifluorometylphenyl 44e 88 92 
46 23e n-butyl 4-trifluoromethylphenyl 45e 86 91 
47 23e n-butyl 3, 5-dimethylphenyl 46e 92 97 
48 23e n-butyl 3-trifluoromethylphenyl 47e 88 87 
49 23f benzyl n-butyl 24f 70 16 
50 23f benzyl t-butyl 25f 54 48 
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51 23f benzyl 4-ethylbutanoate 26f 72 98 
52 23f benzyl 2-methylphenyl 27f 87 99 
53 23f benzyl 4-methylphenyl 28f 88 97 
54 23f benzyl 4-cyanophenyl 29f 97 99 
55 23f benzyl 3-cyanophenyl 30f 92 100 
56 23f benzyl phenyl 31f 88 99 
57 23f benzyl benzyl 32f 100 76 
58 23f benzyl 3-phenylpropyl 33f 75 97 
59 23f benzyl 2-(4-ethylphenyl)ethyl 34f 94 97 
60 23f benzyl 2-methoxyphenyl 35f 80 98 
61 23f benzyl 3-fluoroohenyl 36f 75 99 
62 23f benzyl 4-fluorophenyl 37f 82 99 
63 23f benzyl 3-bromophenyl 38f 90 84 
64 23f benzyl 4-bromophenyl 39f 92 94 
65 23f benzyl 2-chlorophenyl 40f 90 98 
66 23f benzyl 3-chlorophenyl 41f 82 98 
67 23f benzyl 4-chlorophenyl 42f 92 86 
68 23f benzyl 5-benzo[d][1,3]dioxole 43f 97 100 
69 23f benzyl 3-trifluorometylphenyl 44f 100 100 
70 23f benzyl 4-trifluoromethylphenyl 45f 100 100 
71 23f benzyl 3, 5-dimethylphenyl 46f 100 100 
72 23f benzyl 4-(N, N-dimethylamino)phenyl 47f 69 47 
a. HPLC methods of purification and analysis used for these compounds are provided in detail in the experimental section. 
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Table 5. Molecular properties 
Entry Compound M. W. HBA HBD Rot. Bonds PSA CLogP 
1 18a 346 3 1 4 60.78 2.20 
2 18b 358 4 1 5 67.51 1.98 
3 18c 308 4 0 3 62.54 0.84 
4 18d 294 3 1 5 61.5 1.91 
5 18e 320 3 1 3 49.77 2.35 
6 18f 328 3 1 4 55.61 2.06 
7 18g 407 3 1 4 55.61 2.92 
8 18h 342 3 1 4 48.71 2.56 
9 18i 388 5 1 6 69.06 2.07 
10 18j 252 3 1 2 56.84 0.32 
11 18k 280 3 1 4 56.49 1.38 
12 18l 280 3 1 3 44.29 1.16 
13 18m 282 4 2 4 99.40 0.24 
14 18n 323 3 2 6 58.58 1.01 
15 18o 329 4 2 4 72.96 0.56 
16 18p 381 3 2 5 79.79 2.41 
17 18q 306 3 0 3 53.02 2.13 
18 18r 382 3 0 4 53.02 3.54 
19 18s 321 3 1 3 55.00 1.41 
20 18t 383 4 1 4 55.00 2.84 
21 18u 447 5 0 5 78.97 2.52 
22 18v 411 4 0 5 74.67 2.01 
23 18w 349 4 0 4 83.03 0.43 
24 18x 417 4 0 5 102.55 1.79 
25 20a 328 2 2 3 21.41 4.23 
26 20b 328 2 2 3 23.99 4.18 
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27 20c 344 3 2 5 41.98 3.23 
28 20d 306 2 2 3 35.61 3.03 
29 20e 318 2 2 3 23.99 3.59 
30 20f 314 2 2 3 16.31 3.73 
31 20g 368 2 2 3 16.32 4.49 
32 20h 368 2 2 3 14.71 3.61 
33 20i 330 3 2 4 17.45 3.28 
34 20j 314 2 2 3 15.18 3.73 
35 20k 379 2 2 3 16.31 4.31 
36 20l 379 2 2 3 16.31 4.31 
37 20m 325 3 2 3 72.18 3.16 
38 20n 343 3 3 4 18.48 3.40 
39 20o 314 2 2 4 27.48 3.31 
40 20p 356 2 2 6 24.42 4.70 
41 20q 306 2 2 3 16.65 3.61 
42 20r 280 2 2 5 28.42 3.16 
43 20s 370 2 2 7 16.39 5.85 
44 20t 280 2 2 2 16.44 2.81 
45 20u 339 2 3 3 42.73 3.23 
46 20v 342 2 2 6 28.43 4.05 
47 20w 325 3 2 3 70.24 3.16 
48 20x 338 4 2 8 59.12 2.77 
49 24e 336 2 2 8 28.37 5.27 
50 25e 394 4 2 11 59.04 4.88 
51 26e 370 2 2 6 14.93 5.28 
52 27e 370 2 2 6 16.02 5.84 
53 28e 381 3 2 6 71.94 5.26 
54 29e 381 3 2 6 70.08 5.26 
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55 30e 356 2 2 6 16.04 5.34 
56 31e 370 2 2 7 27.14 5.42 
57 32e 404 2 2 7 27.11 6.13 
58 33e 398 2 2 9 15.59 6.16 
59 34e 412 2 2 9 24.17 6.81 
60 35e 386 3 2 7 19.14 5.39 
61 36e 374 2 2 6 15.97 5.69 
62 37e 374 2 2 6 16.05 5.69 
63 38e 435 2 2 6 16.02 6.41 
64 39e 435 2 2 6 16.05 6.41 
65 40e 390 2 2 6 15.75 5.70 
66 41e 390 2 2 6 16.13 6.26 
67 42e 390 2 2 6 16.09 6.26 
68 43e 400 4 2 6 37.08 5.36 
69 44e 424 2 2 6 14.28 6.59 
70 45e 424 2 2 6 16.09 6.59 
71 46e 384 2 2 6 14.88 6.34 
72 47e 424 2 2 6 14.43 5.71 
73 24f 370 2 2 7 27.85 5.25 
74 25f 370 2 2 4 16.03 4.90 
75 26f 414 2 4 9 59.12 4.33 
76 27f 404 2 2 5 14.65 5.26 
77 28f 404 2 2 5 15.78 5.82 
78 29f 415 2 3 5 71.63 5.24 
79 30f 415 2 3 5 69.72 5.24 
80 31f 390 2 2 5 15.79 5.32 
81 32f 404 2 2 6 26.60 5.40 
82 33f 432 2 2 8 15.27 6.14 
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83 34f 446 2 2 8 23.87 6.79 
84 35f 420 2 3 6 18.51 5.37 
85 36f 408 2 2 5 15.41 5.68 
86 37f 408 2 2 5 15.49 5.68 
87 38f 469 2 2 5 15.72 6.40 
88 39f 469 2 2 5 15.49 6.40 
89 40f 425 2 2 5 15.43 5.69 
90 41f 425 2 2 5 15.78 6.25 
91 42f 425 2 2 5 15.78 6.25 
92 43f 434 2 4 5 36.76 5.34 
93 44f 458 2 2 5 13.90 6.57 
94 44f 458 2 2 5 15.77 6.57 
95 46f 418 2 2 5 14.33 6.32 
96 24d 294 2 2 5 28.43 3.68 
97 25d 294 2 2 2 16.39 3.33 
98 26d 352 2 4 8 59.15 3.29 
99 28d 328 2 2 3 16.22 4.25 
100 29d 339 2 3 3 72.07 3.68 
101 30d 339 2 3 3 70.16 3.68 
102 31d 382 2 2 3 14.34 5.01 
103 32d 328 2 2 4 27.34 3.83 
104 33d 356 2 2 6 15.71 4.57 
105 34d 370 2 2 6 24.29 5.22 
106 35d 344 2 3 4 19.24 3.80 
107 36d 332 2 2 3 16.15 4.11 
108 37d 332 2 2 3 16.23 4.11 
109 38d 393 2 2 3 16.15 4.83 
110 39d 393 2 2 3 16.23 4.83 
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111 40d 348 2 2 3 15.86 4.12 
112 41d 348 2 2 3 16.22 4.68 
113 42d 348 2 2 3 16.22 4.68 
114 43d 358 2 4 3 37.14 3.77 
115 44d 382 2 2 3 14.34 5.01 
116 45d 382 2 2 3 16.23 5.01 
117 46d 342 2 2 3 15.07 4.75 
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CHAPTER 3 
 
EXPERIMENTAL SECTION 
 
 General Procedures. All non-aqueous reactions were carried out in oven- or flame-dried 
flasks under argon atmosphere. CH2Cl2, THF, and MeCN were dried by using Innovative 
Technology Pure-Solv 400 commercial solvent purification system. Microwave reactions were 
carried out using a Biotage Initiator equipped with robot automation. Parallel syntheses were 
conducted with 24-position Mettler-Toledo Bohdan MiniBlocks, and parallel evaporations were 
carried using a Techne sample concentrator and a GeneVac EZ-2 personal evaporator. HPLC 
analysis was carried out using a Waters Acquity system with UV detection and mass detection 
(Waters LCT Premier). The analytical method utilized a linear gradient of 5% CH3CN in pH 9.8 
buffered aqueous NH4HCO2 to 100% CH3CN at a flow rate of 0.6 mL/min. Purity was 
determined using UV peak area at 214 nm. Preparative reverse-phase HPLC purification was 
performed using a Waters 2767 preparative system with UV detection (Waters 2996 PAD) and 
mass detection (Waters Micromass ZQ). The preparative method utilized a Waters X-Bridge C18 
column (19 x 150 mm, w/ 19 x 10 mm guard column), elution with a water and CH3CN gradient 
which increases 20% in CH3CN content over 4 minutes at a flow rate of 20 mL/min (modified to 
pH 9.8 through addition of NH4OH by auxiliary pump), and sample dilution in DMSO. Thin-
layer chromatography (TLC) was performed using commercial Analtech glass-backed silica 
plates (250 microns) with an organic binder. Visualization was accomplished using UV light or 
aqueous KMnO4. Flash chromatography was carried out using Sorbent Technologies standard 
grade silica gel (40-63 µm particle size, 230 Å~ 400 mesh) with compressed nitrogen as a source 
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of positive pressure. Melting points were performed in open capillary tubes using either a Mel-
Temp or Thomas Hoover capillary melting point apparatus and are uncorrected. Infrared (IR) 
spectra were acquired as thin films on a PerkinElmer Spectrum 100 FT-IR spectrometer, and the 
absorptions are reported in cm-1. 1H and 13C NMR spectra were recorded on a Bruker AM 400 
spectrometer (operating at 400 and 100 MHz respectively) in CDCl3 with 0.03% TMS as an 
internal standard. Chemical shifts are reported in parts per million (ppm), and referenced to 
CDCl3 with CHCl3 as internal reference (7.26 ppm for 1H and 77.23 ppm for 13C. Coupling 
constants are reported in Hertz (Hz). High resolution mass spectra were obtained using a Waters 
LCT Premier instrument with a time of flight (TOF) mass analyzer and an electrospray ion 
source (ESI). 
Materials. All starting materials were purchased from Aldrich, Fluka or Fischer Chemical 
companies and used as received. The following compounds 7 through 15 were prepared by 
following reported procedures. We have prepared compounds 8 and 14 on significantly larger 
scales than the previously reported synthesis.38 Large-scale synthesis of these compounds was 
also carried out via improved alternative procedures. Experimental procedures for both old and 
new routes are provided below. 
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Bicyclo[2.2.1]heptane-2,5-dione (8).  In a 1L round bottom flask, 100 g of 2, 5-norbornadiene 
was added. The 600 mL of formic acid (97%) was added to it under argon atmosphere. The 
reaction was refluxed at 120 ºC for 24h. Finally the formic acid was distilled off and the 
diformate was obtained by vacuum distillation (120-130 ºC at 10 mmHg) as clear liquid. 
Diformate was transformed to 23 via two different methods (method A and B) as described 
below.  
Method A: 100 g of diformate  (0.53 mol) was transferred into a 2L round bottom flask kept in a 
large ice bath and fitted with a mechanical stirrer. 300 mL of acetone was added to it. The 
solution was cooled to 0 ºC. At this temperature 700 mL (8N) of Jones reagent was added 
dropwise over a period of 2 h. The reaction mixture was allowed to come to room temperature 
for over night. Following this the reaction was repeatedly extracted with diethyl ether (700 mL x 
4). The combined organic layer was transferred to another 4L round bottom flask and cooled to 0 
ºC by keeping in ice-water bath. Solid sodium carbonate was added in portions to this solution 
till no more effervescence was seen. The solvent was decanted and concentrated under reduced 
pressure to obtain 12 g (19%) of diketone 8 as a low melting solid. 
Method B: In a 3L round bottom flask containg 1.5 L of THF, was added 200 g (1.06 mol) of 
diformate. The solution was cooled to 0 ºC and NaOH (424 g in 600 mL water) solution was 
added to it via a dropping funnel in 30 min. The reaction mixture was stirred at room temperature 
for 10h was transeferred to a 4 L separating funnel and extracted with ethylacetate. Organic layer 
was separated and the aqueous layer was again extracted with ethyl acetate on saturating with 
sodium chloride. The combined organic layer was dried over anhydrous sodium sulfate, filtered 
and concentrated to obtain 100 g of crude diol as a white solid. The diol was vacuum dried for 4h 
and transferred to a three-neck 4L round bottom flask fitted with a mechanical stirred.  225 mL 
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of anhydrous dimethylsulfoxide was added to it and the mixture was stirred till the solution 
became completely clear. Then the solution was diluted with dichloromethane (800 mL) and 
phosphorous pentoxide (450 g, 1.58 mol) was charged into it. The reaction mixture was stirred 
vigorously for 1h at rt. Then it was cooled to 0 ºC on keeping in ice-water bath. Triethyl amine 
(661 mL, 4.75 mol) was added to it dropwise over a period of 1 h. The reaction was stirred at 0 
ºC for further 1 h before it was quenched with 10% HCl (800 mL). Finally it was transferred to a 
separating funnel and was extracted with dichloromethane. The combined organic layer was 
dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified 
by flash coulumn chromatography to obtain 80 g of the diketone 8 in 60% yield. 
 
 
 
 
 
(1S,4S,6S)-6-(4-azidobutyl)spiro[bicyclo[2.2.1]heptane-2,2'-[1,3]dioxolan]-5-one (14).  
Compound 12 (10 g, 41.6 mmol) was dissolved in 200 mL of CH2Cl2 and the solution was 
cooled to 0 °C under argon. Methanesulfonyl chloride (4.83 mL, 62.4 mmol) and triethylamine 
(8.68 mL, 62.4 mmol) were added dropwise and the mixture was stirred for 1 h at 0 °C. The 
reaction was quenched with saturated NH4Cl, extracted with EtOAc, and the combined organic 
layers dried over Na2SO4. The solvent was evaporated to obtain the mesylate product. The 
product was dried over high vacuum for 30 min and the residue was dissolved in 100 mL of 
DMF. Sodium azide (9.42 g, 14.5 mmol) was added to the solution and the mixture was stirred at 
50 ºC for 7 h. The reaction was diluted with water, extracted with EtOAc; the combined organic 
layers were dried over Na2SO4. Concentration followed by chromatography (10% 
O
O
OHN3
14
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EtOAc/hexane) afforded 10.14 g (92%) of 14 isolated as a colorless liquid. 
 
 
 
 
 
(7S,10S,10aS)-octahydro-7,10-methanopyrido[1,2-a]azepine-6,9-dione (15). Azide 14 (10 g, 
37.7 mmol) was dissolved in 350 mL of CH2Cl2 under argon and cooled to 0 °C. TiCl4 (20.7 mL, 
188.5 mmol) was added dropwise by syringe. A yellow precipitate was formed. The reaction was 
allowed to warm to room temperature and stirred for 24 h. The reaction was quenched with water 
and the aqueous layer was extracted with CH2Cl2. The organic layer was dried over Na2SO4 and 
concentrated to give a oil. Flash chromatography (100% EtOAc) afforded 4.5 g (62%) of 15 
isolated as white solid. 
   
 
 
(7S,10S,10aS)-hexahydro-1H-spiro[7,10-methanopyrido[1,2-a]azepine-9,2'-[1,3]dioxolan]-
6(2H)-one (21). Chlorotrimethylsilane (13.1 mL, 103.2 mmol) was added to a solution of 15 (5 
g, 25.89 mmol) in dry ethylene glycol (80 mL) under an argon atmosphere and the reaction 
mixture stirred for 6 h at room temperature. Water (50 mL) was added and the mixture was 
extracted with diethylether. The organic layer was dried over anhydrous sodium sulfate. 
Concentration followed by flash column chromatography gave 4.29 g (70 %) of 21 as a white 
solid (m.p. 90-91 ºC):  1H NMR (400 MHz, CDCl3) δ 4.52 (ddt, J = 13.3, 4.2, 2.0 Hz, 1H), 4.04 
O
N
H
O
15
N
H
O
O
O
21
	   46 
– 3.69 (m, 4H), 3.19 (dt, J = 12.3, 2.9 Hz, 1H), 2.69 (ddd, J = 7.3, 4.5, 1.6 Hz, 1H), 2.36 (td, J = 
13.0, 3.2 Hz, 1H), 2.27 – 1.98 (m, 5H), 1.87 – 1.73 (m, 2H), 1.70 – 1.58 (m, 1H), 1.58 – 1.46 (m, 
1H), 1.42 – 1.16 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 174.26, 117.13, 65.17, 63.29, 61.16, 
45.98, 42.16, 41.98, 41.21, 32.52, 29.78, 25.25, 25.02; IR (neat) 1638, 2940, cm-1; HRMS calcd 
for (M+ +1): 237.138, found 237.1365. 
Synthesis of the scaffolds 
 
 
 
 
 
(7S,9S,10S,10aS)-9-hydroxyoctahydro-7,10-methanopyrido[1,2-a]azepin-6(2H)-one (16). 
Lactam 15 (500 mg, 2.58 mmol) was dissolved in methanol. The solution was cooled to 0 °C and 
sodiumborohydride (196 mg, 5.178 mmol) was added to it. The reaction mixture was stirred at 
room temperature for 4h. The reaction mixture was quenched with 10% aq. NaOH solution and 
was extracted with ethyl acetate. The organic layer was dried over anhyd.Na2SO4 and 
concentrated to give the crude product. The crude product was purified by flash column 
chromatography to obtain 444 mg  (88%) of 16 as a the only diastereomer. 1H NMR (400 MHz, 
CDCl3) δ 4.60 – 4.38 (m, 2H), 3.32 (d, J = 12.4 Hz, 1H), 3.12 (s, 1H), 2.67 – 2.51 (m, 1H), 2.48 
– 2.19 (m, 4H), 1.80 (dd, J = 12.8, 1.6 Hz, 1H), 1.75 – 1.53 (m, 5H), 1.43 – 1.10 (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ 175.12, 75.30, 62.72, 43.12, 42.23, 42.09, 38.28, 31.80, 30.57, 25.51, 
25.19; IR (neat) 1623, 2931, 3355 cm-1; HRMS calcd for (M+ +1): 195.1271, found 195.1259. 
 
 
N
H
O
OH
H
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(7S,9S,10S,10aS)-6-oxodecahydro-7,10-methanopyrido[1,2-a]azepin-9-yl 4-bromobenzoate 
(16a). To a solution of 16 (50 mg, 0.25 mmol) in dichloromethane (3 mL) was added 
triethylamine (0.071 mL, 0.51 mmol) and N, N-dimethylaminopyridine (2 mg). Then p-
bromobenzoyl chloride was added to it and the reaction mixture was stirred at room temperature 
for 8h. Finally the solvent was evaporated and the crude reaction mixture was purified by flash 
column chromatography to obtain 89 mg (92%) of 16a as a white solid: 1H NMR (400 MHz, 
CDCl3) δ 7.98 – 7.74 (m, 1H), 7.71 – 7.44 (m, 1H), 5.56 – 5.27 (m, 1H), 4.64 – 4.40 (m, 1H), 
3.45 – 3.22 (m, 1H), 2.82 – 2.70 (m, 1H), 2.56 (ddd, J = 14.4, 10.5, 8.1 Hz, 1H), 2.41 (td, J = 
13.0, 3.1 Hz, 1H), 1.97 – 1.82 (m, 2H), 1.81 – 1.64 (m, 1H), 1.64 – 1.54 (m, 1H), 1.44 – 1.15 (m, 
1H); 13C NMR (101 MHz, CDCl3) δ 174.13, 165.81, 131.94, 131.11, 128.79, 128.40, 77.39, 
77.07, 77.04, 76.76, 62.13, 42.09, 41.52, 41.39, 35.12, 31.74, 30.42, 25.46, 25.26; IR (neat) 
1647, 1716, 2938 cm-1;HRMS calcd for (M+ +1): 377.0645, found 377.0627. 
 
 
 
 
 
(6R,7S,10S,10aS)-6-methyloctahydro-7,10-methanopyrido[1,2-a]azepin-9(6H)-one (22d). To 
a stirring solution of lactam 21 (500 mg, 2.1 mmoL) in dry THF (20 mL) was added a solution of 
MeMgCl in THF (2.8 mL, 3M in THF) was added dropwise. After the mixture was allowed to 
N
H O
H
O
O
Br
N
H
H
H3C
O
22d
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heat at 60 °C for 3 h, it was then cooled to 0 °C. Then NaBH3CN (792 mg, 12.6 mmoL) was 
added followed by addition of glacial acetic acid (1.0 mL). The resultant mixture was stirred for 
1 h and was quenched with 10% NaOH solution. It was extracted with ethylacetate. The 
combined organic layer was dried over anhydrous sodium sulfate and concentrated. The residue 
obtained on concentration was dissolved in a mixture of conc. HCl (2 mL) and acetone (20 mL) 
and was refluxed for 2h. The reaction mixture was cooled to 0 °C and neutralized by adding 10 
%  aq.NaOH. Finally it was extracted with ethylacetate and the combined organic layer was 
dried over anhyd. sodium sulfate. Concentration followed by flash column chromatography gave 
354 mg (87%) of 22d as a colorless liquid. 1H NMR (400 MHz, CDCl3) δ 3.05 (dd, J = 7.3, 3.9 
Hz, 1H), 2.42 (dd, J = 6.3, 1.4 Hz, 1H), 2.28 (dt, J = 10.7, 5.3 Hz, 2H), 2.15 (dd, J = 10.5, 3.2 
Hz, 1H), 2.07 – 1.89 (m, 3H), 1.88 – 1.76 (m, 1H), 1.75 – 1.61 (m, 3H), 1.59 – 1.10 (m, 7H), 
1.06 (d, J = 6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 218.42, 67.31, 60.99, 52.04, 51.03, 
40.34, 39.63, 37.16, 30.12, 25.72, 24.44, 18.85; IR (neat) 1733, 2932 cm-1; HRMS calcd for (M+ 
+1): 194.1546, found 194.1554. 
 
 
 
 
 
(6R,7S,10S,10aS)-6-butyloctahydro-7,10-methanopyrido[1,2-a]azepin-9(6H)-one (22e). 
 
1H NMR (400 MHz, CDCl3) δ 3.08 (d, J = 11.2 Hz, 1H), 2.42 (s, 1H), 2.27 – 2.03 (m, 3H), 2.01 
– 1.84 (m, 3H), 1.71 (dd, J = 11.0, 3.6 Hz, 1H), 1.67 – 1.55 (m, 3H), 1.55 – 1.02 (m, 10H), 0.83 
(dd, J = 10.0, 4.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 67.46, 66.35, 52.05, 51.04, 39.72, 
N
H
H
nBu
O
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36.76, 36.57, 31.24, 30.31, 29.53, 25.78, 24.42, 23.00, 14.02; IR (neat); 2933, 1741 cm-1; HRMS 
calcd for (M+ +1): 235.1954, found 235.1936. 
 
 
 
 
 
 
(6R,7S,10S,10aS)-6-benzyloctahydro-7,10-methanopyrido[1,2-a]azepin-9(6H)-one (22f). 
 
1H NMR (400 MHz, CDCl3) δ 7.30 (dd, J = 10.1, 4.5 Hz, 2H), 7.21 (dd, J = 8.4, 6.3 Hz, 1H), 
7.17 – 7.08 (m, 2H), 3.34 (d, J = 11.2 Hz, 1H), 3.20 (dd, J = 13.6, 4.1 Hz, 1H), 2.58 (ddd, J = 
9.9, 4.1, 1.4 Hz, 1H), 2.41-2.36 (m, 2H), 2.27 – 2.14 (m, 2H), 2.07 – 1.78 (m, 4H), 1.78 – 1.38 
(m, 6H), 1.35 – 1.14 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 217.74, 139.79, 129.35, 128.47, 
126.10, 67.71, 67.50, 52.14, 51.30, 39.45, 37.55, 36.64, 35.24, 30.40, 25.89, 24.46; IR (neat) 
1740, 2935 cm-1; HRMS calcd for (M+ +1): 269.1802, found 269.178. 
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Library Synthesis 
 
 
Procedure for the synthesis of lactams 18a-x. To a solution alcohol 16 (1.5 g, 7.68 mmol) in 
anhydrous THF (40 mL), pyridine (0.92 mL, 11.5 mmol) and 4-nitorphenyl chloroformate (1.86 
g, 9.2 mmol) were added sequentially. The reaction mixture was stirred at room temperature for 
2h. The solvent was evaporated and the crude residue was purified by flash column 
chromatography to yield 2.62 g (95%) of 17 as white solid. To each reaction tube of a 24-
position Bohdan MiniBlock XT was added a solution of 17 in 1, 2-dichloroethane (2.1mL, 0.12 
M), the appropriate amine (1.26 mmol) was added via syringe. The reactions were shaken for 4 
hours at 450 rpm, and then 20 % HCl (3 mL) was added to each tube. The reactions were shaken 
for 15 additional minutes, and then passed into hydrophobic phase separator tubes, which 
allowed the halogenated organic layer to pass through into the collection tubes. The phase 
separators were closed, CH2Cl2 (3 mL) was added to each, and then shaking was continued for 
10 minutes. The organic layers were again passed into the collection tubes containing the 
solutions from the first separation. Solvents were removed using a sample concentrator, and the 
reaction products were subjected to mass-directed preparative HPLC purification to give the 
product. 
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 Procedure for the synthesis of amines 20a-x. Lactam 15 (2 g, 10.32 mmol) was dissolved in 
methanol. The solution was cooled to 0 °C and sodiumborohydride (784 mg, 20.71 mmol) was 
added to it. The reaction mixture was stirred at room temperature for 4h. The reaction mixture 
was quenched with 10% aq. NaOH solution and was extracted with ethyl acetate. The organic 
layer was dried over anhyd. Na2SO4 and concentrated to give the product 19 which was taken for 
the library development without further chromatpgraphic purification. To each pyrex glass vial 
placed on a 24-position block was added a solution of 19 in acetonitrile (1 mL, 0.5 M), the 
appropriate isocyanate (1 mmol ) was added to each vial. The vials were irradiated in microwave 
at 110 ºC for 1 h and then the contents of each vial were transferred to a phase separators fitted 
on a 24 position Mini Block. Dichloromethane (3 mL) and saturated sodiumbicarbonate solution  
(3 mL) were added to each tube. The reactions were shaken for 15 minutes, and then allowed the 
halogenated organic layer to pass through into the collection tubes. The phase separators were 
closed, CH2Cl2 (3 mL) was added to each, and then shaking was continued for 10 minutes. The 
organic layers were again passed into the collection tubes containing the solutions from the first 
separation. Solvents were removed using a sample concentrator, and the reaction products were 
subjected to mass-directed preparative HPLC purification to give the product. 
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Procedure for the synthesis of amines 24. 7.77 mmol of 22 was dissolved in methanol (40 
mL). The solution was cooled to 0 °C and sodiumborohydride (23.31 mmol) was added to it. The 
reaction mixture was stirred at room temperature for 4h. The reaction mixture was quenched 
with 10% aq. NaOH solution and was extracted with ethyl acetate. The organic layer was dried 
over anhyd. Na2SO4 and concentrated to obtain amino-alcohol 23 as a liquid. To be noted that 
the product was highly polar and not considered suitable for purification by column 
chromatography so was taken as such ahead for next step. To each reaction tube of a 24-position 
Bohdan MiniBlock XT was added a solution of 23 in THF (1 mL, 0.25 M), the appropriate 
isocyanate (0.5 mmol) was added. The reactions were shaken for 7 hours at 450 rpm. Then 
saturated NaHCO3 (2 mL) and dichloromethane (4 mL) were added to each tube. The reactions 
were shaken for 15 additional minutes, and then passed into hydrophobic phase separator tubes, 
which allowed the halogenated organic layer to pass through into the collection tubes. The phase 
separators were closed, CH2Cl2 (3 mL) was added to each, and then shaking was continued for 
10 minutes. The organic layers were again passed into the collection tubes containing the 
solutions from the first separation. Solvents were removed using a sample concentrator, and the 
reaction products were subjected to mass-directed preparative HPLC purification to give the 
product. 
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Spectral data of the representative members of the library compounds is listed below.  
 
(7S,9S,10S,10aS)-6-oxodecahydro-7,10-methanopyrido[1,2-a]azepin-9-yl 4-
fluorobenzylcarbamate: 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.11 (m, 2H), 7.10 – 6.88 (m, 
2H), 5.35 – 5.00 (m, 2H), 4.62 – 4.44 (m, 1H), 4.36 – 4.27 (m, 2H), 3.40 – 3.25 (m, 1H), 2.75 – 
2.60 (m, 2H), 2.52 – 2.25 (m, 2H), 2.00 – 1.50 (m, 7H), 1.45 – 1.03 (m, 2H); 13C NMR (101 
MHz, CDCl3) δ174.3, 163.4, 160.9, 156.1, 134.3, 129.3, 129.2, 115.6, 115.4, 62.2, 44.3, 42.0, 
41.4, 35.0, 30.2, 25.5, 25.2; IR (neat) ; IR (neat) 1634, 1709, 2943 cm-1; HRMS calcd for (M+ 
+1): 347.1771, found 347.1798. 
 
 
 
(7S,9S,10S,10aS)-6-oxodecahydro-7,10-methanopyrido[1,2-a]azepin-9-yl 4-
methoxybenzylcarbamate: 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.04 (m, 2H), 6.95 – 6.65 (m, 
2H), 5.33 – 4.93 (m, 2H), 4.62 – 4.44 (m, 1H), 4.39 – 4.18 (m, 2H), 3.76 (s, 3H), 3.40 – 3.25 (m, 
1H), 2.77 – 2.52 (m, 2H), 2.52 – 2.22 (m, 2H), 2.02 – 1.47 (m, 7H), 1.44 – 1.04 (m, 2H); 13C 
NMR (101 MHz, CDCl3) δ 174.3, 159.0, 156.0, 130.6, 128.9, 114.0, 76.7, 62.1, 55.3, 44.5, 42.0, 
41.4, 41.3, 35.0, 31.4, 30.1, 25.5, 25.1; IR (neat) 1634, 1710, 2941 cm-1; HRMS calcd for (M+ 
+1): 359.1971, found 359.2099. 
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(7S,9S,10S,10aS)-6-oxodecahydro-7,10-methanopyrido[1,2-a]azepin-9-yl morpholine-4-
carboxylate: 1H NMR (400 MHz, CDCl3) δ 5.17 (dt, J = 11.1, 5.8 Hz, 1H), 4.74 – 4.35 (m, 1H), 
4.00 – 3.10 (m, 9H), 2.74 – 2.59 (m, 2H), 2.50 – 2.28 (m, 2H), 1.89 – 1.53 (m, 7H), 1.39 – 1.15 
(m, 2H); 13C NMR (101 MHz, CDCl3) δ 174.2, 154.8, 76.7, 66.5, 62.0, 44.3, 43.9, 41.9, 41.4, 
41.2, 35.0, 30.2, 25.4, 25.3; IR (neat) 1636, 1697, 2943 cm-1; HRMS calcd for (M+ +1): 
309.1814, found 309.2050. 
 
 
(7S,9S,10S,10aS)-6-oxodecahydro-7,10-methanopyrido[1,2-a]azepin-9-yl butylcarbamate. 
1H NMR (400 MHz, CDCl3) δ 5.24 – 4.76 (m, 2H), 4.54 – 4.44 (m, 1H), 3.35 – 3.20 (m, 1H), 
3.11 – 2.98 (m, 2H), 2.46 – 2.20 (m, 4H), 1.95 – 1.50 (m, 7H), 1.47 – 1.06 (m, 6H), 0.83 (t, J = 
7.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 174.3, 156.0, 76.3, 62.1, 41.9, 41.3, 41.2, 40.6, 34.9, 
31.9, 31.4, 29.9, 25.4, 25.1, 19.7, 13.6; IR (neat) 1635, 1711, 2938 cm-1; HRMS calcd for (M+ 
+1): 295.2021, found 295.2288. 
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(7S,9S,10S,10aS)-6-oxodecahydro-7,10-methanopyrido[1,2-a]azepin-9-yl 2-
cyclohexylacetate:1H NMR (400 MHz, CDCl3) δ 5.37 – 4.95 (m, 1H), 4.80 – 4.36 (m, 2H), 3.60 
– 3.20 (m, 2H), 2.75 – 2.25 (m, 4H), 2.20 – 1.45 (m, 12H), 1.45 – 1.00 (m, 7H). 13C NMR (101 
MHz, CDCl3) δ 174.3, 155.2, 76.3, 62.1, 49.8, 42.0, 41.4, 41.3, 34.9, 33.5, 33.2, 31.4, 30.0, 25.5, 
25.4, 25.2, 24.8, 24.7; IR (neat) 1635, 1710, 2936 cm-1; HRMS calcd for (M+ +1): 321.2178, 
found 321.2421. 
 
 
(7S,9S,10S,10aS)-6-oxodecahydro-7,10-methanopyrido[1,2-a]azepin-9-yl (pyridin-3-
ylmethyl)carbamate:1H NMR (400 MHz, CDCl3) δ 8.60 – 8.25 (m, 2H), 7.61 (d, J = 7.8 Hz, 
1H), 7.38 – 7.07 (m, 1H), 6.11 (t, J = 5.8 Hz, 1H), 5.14 (dt, J = 10.8, 5.5 Hz, 1H), 4.57 – 4.25 
(m, 3H), 3.35 – 3.15 (m, 1H), 2.36 – 2.29 (m, 4H), 1.93 – 1.36 (m, 7H), 1.30 – 0.90 (m, 2H); 13C 
NMR (101 MHz, CDCl3) δ 174.3, 156.2, 148.9, 148.6, 135.4, 134.4, 123.5, 76.7, 62.1, 42.4, 
42.0, 41.4, 41.2, 35.1, 31.4, 30.0, 25.4, 25.1; IR (neat) 1635, 1712, 2940, 3261 cm-1; HRMS 
calcd for (M+ +1): 330.1820, found 330.1818. 
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(7S,9S,10S,10aS)-decahydro-7,10-methanopyrido[1,2-a]azepin-9-yl(3-
phenylpropyl)carbamate: 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.03 (m, 5H), 5.25 – 4.75 (m, 
2H), 3.43 – 2.90 (m, 3H), 2.90 – 2.70 (m, 2H), 2.70 – 2.30 (m, 4H), 2.25 – 1.25 (m, 13H), 1.30 – 
1.10 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 156.8, 141.5, 128.4, 128.3, 125.9, 67.9, 63.2, 56.6, 
42.4, 40.8, 40.4, 37.5, 34.1, 33.9, 33.0, 31.6, 30.6, 25.5, 25.3; IR (neat) 1695, 2934 cm-1 ; HRMS 
calcd for (M+ +1): 343.2387, found 343.2325. 
 
 
Ethyl 4-(7S,9S,10S,10aS)-decahydro-7,10-methanopyrido[1,2-a]azepin-9-
yl)oxy)carbonyl)amino)butanoate:1H NMR (400 MHz, CDCl3) δ 5.21 – 4.90 (m, 1H), 4.09 (q, 
J = 7.1 Hz, 2H), 3.50 – 2.80 (m, 4H), 2.80 – 2.60 (m, 2H), 2.31 (t, J = 7.4 Hz, 2H), 2.22 – 1.44 
(m, 13H), 1.44 – 1.29 (m, 2H), 1.21 (t, J = 8 Hz, 3H), 1.21 – 0.99 (m, 1H); 13C NMR (101 MHz, 
CDCl3) δ 173.2, 156.8, 76.7, 67.8, 63.1, 60.4, 56.6, 42.3, 40.9, 40.2, 37.4, 34.0, 33.9, 31.4, 30.6, 
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25.5, 25.2, 14.1; IR (neat) 1715, 2934 cm-1; HRMS calcd for (M+ +1): 339.2285, found 
339.2277. 
 
 
(6R,7S,9S,10S,10aS)-6-methyldecahydro-7,10-methanopyrido[1,2-a]azepin-9-yl]4-
chlorobenzylcarbamate. 1H NMR (400 MHz, CDCl3) δ 7.28 (dd, J = 4.7, 3.6 Hz, 2H), 7.23 (d, 
J = 8.3 Hz, 2H), 5.35 (bs, 1H), 5.10 (dt, J = 10.8, 5.4 Hz, 1H), 4.38 (dd, J = 15.2, 6.4 Hz, 1H), 
4.28 (dd, J = 15.2, 5.9 Hz, 1H), 3.30 – 3.10 (m, 1H), 2.15 – 1.92 (m, 4H), 1.89 – 1.42 (m, 9H), 
1.37 (d, J = 12.4 Hz, 1H), 1.27 – 1.08 (m, 1H), 1.03 (d, J = 8.0 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 156.8, 137.3, 133.0, 128.8, 128.6, 68.3, 63.7, 52.7, 44.3, 43.1, 41.0, 40.9, 37.7, 31.2, 
29.9, 25.9, 25.7, 18.3; IR (neat) 1704, 2935 cm-1; HRMS calcd for (M+ +1): , found. 
 
(6R,7S,9S,10S,10aS)-6-methyldecahydro-7,10-methanopyrido[1,2-a]azepin-9-yl(3-
phenylpropyl)carbamate. 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.24 (m, 2H), 7.19 (dd, J = 
10.2, 4.5 Hz, 3H), 5.10 (dt, J = 10.8, 5.4 Hz, 1H), 4.96 (bs, 1H), 3.34 – 3.08 (m, 3H), 2.79 – 2.49 
(m, 4H), 2.14 – 1.98 (m, 4H), 1.93 – 1.33 (m, 10H), 1.25 – 1.05 (m, 1H); 1.05 (d, J = 8.0 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 156.8, 141.5, 128.4, 128.3, 125.9, 68.4, 63.7, 52.8, 43.1, 
41.0, 40.9, 40.4, 37.7, 33.0, 31.6, 31.2, 29.9, 26.0, 25.8, 18.3; IR (neat) 1697, 2931 cm-1; HRMS 
calcd for (M+ +1): , found. 
N
H O
H
H
N
O
Cl
H
Me
N
H O
H
H
N
O
H
Me
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(6R,7S,9S,10S,10aS)-6-butyldecahydro-7,10-methanopyrido[1,2-a]azepin-9-yl(2-
methoxyphenyl)carbamate. 1H NMR (400 MHz, CDCl3) δ 8.12 (dd, J = 7.6, 2.1 Hz, 1H), 7.39 
(bs, 1H), 7.05 – 6.89 (m, 2H), 6.87 – 6.76 (m, 1H), 5.18 (dt, J = 10.9, 5.6 Hz, 1H), 3.83 (s, 3H), 
3.40 – 3.25 (m, 1H), 2.21 (m, 1H), 2.13 – 1.95 (m, 3H), 1.96 – 1.00 (m, 17H), 0.89 (t, J = 7.1 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 153.7, 147.6, 127.9, 122.4, 121.0, 118.1, 109.9, 77.5, 69.4, 
68.9, 55.5, 52.9, 43.1, 37.3, 37.1, 31.4, 30.7, 29.8, 29.6, 26.1, 25.8, 23.0, 14.0; IR (neat) 1602, 
1723, 2935 cm-1; HRMS calcd for (M+ +1): 386.264, found 387.2618. 
 
 
(6R,7S,9S,10S,10aS)-6-butyldecahydro-7,10-methanopyrido[1,2-a]azepin-9-yl (4-
cyanophenyl)carbamate 
1H NMR (400 MHz, CDCl3) δ 7.65 – 7.37 (m, 5H), 5.15 (dt, J = 11.0, 5.5 Hz, 1H), 3.28 (d, J = 
11.2 Hz, 1H), 2.20 – 2.15 (m, 1H), 2.11 – 1.95 (m, 3H), 1.89 (d, J = 6.7 Hz, 1H), 1.85 – 1.34 (m, 
11H), 1.34 – 1.05 (m, 6H), 0.86 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 153.26, 
142.6, 133.2, 119.0, 118.2, 105.7, 78.1, 69.2, 68.6, 52.7, 43.0, 40.9, 37.1, 31.5, 30.7, 30.1, 29.5, 
N
H O
H
H
N
O
OCH3
nBu
H
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26.0, 25.7, 23.0, 14.0. IR (neat) 1596, 1727, 2222, 2931 cm-1; HRMS calcd for (M+ +1): 
382.2496, found 382.2486. 
 
 
 
(6R,7S,9S,10S,10aS)-6-benzyldecahydro-7,10-methanopyrido[1,2-a]azepin-9-yl]o-
tolylcarbamate:1H NMR (400 MHz, CDCl3) δ 7.77 (s, 1H), 7.29 (dd, J = 8.1, 6.6 Hz, 2H), 7.25 
– 7.10 (m, 5H), 7.04 (t, J = 7.3 Hz, 1H), 6.63 (s, 1H), 5.17 (dt, J = 10.9, 5.6 Hz, 1H), 3.60 – 3.40 
(d, J = 10.3 Hz, 1H), 3.20 (dd, J = 13.3, 2.7 Hz, 1H), 2.50 – 1.20 (m, 19H); 13C NMR (101 MHz, 
CDCl3) δ 153.8, 140.2, 136.0, 130.4, 129.5, 128.3, 126.7, 125.9, 124.2, 70.6, 68.7, 52.9, 43.1, 
41.0, 37.2, 37.1, 35.8, 31.4, 29.7, 26.1, 25.7, 17.9; IR (neat) 1720, 2935 cm-1; HRMS calcd for 
(M+ +1): 405.2543, found 405.2528. 
 
 
 
(6R,7S,9S,10S,10aS)-6-benzyldecahydro-7,10-methanopyrido[1,2-a]azepin-9-yl p-
tolylcarbamate: 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.25 (m, 4H), 7.25-7.21 (m, 1H), 7.18 – 
7.06 (m, 4H), 6.85 (s, 1H), 5.19 (dt, J = 10.9, 5.5 Hz, 1H), 3.57 (d, J = 11.1 Hz, 1H), 3.21 (dd, J 
= 13.3, 2.9 Hz, 1H), 2.63 (s, 3H), 2.40 – 2.35 (m, 1H), 2.25 – 1.60 (m, 12H), 1.60 – 1.40 (m, 
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1H), 1.37 (dd, J = 11.6, 2.3 Hz, 1H), 1.31 – 1.12 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 153.8, 
140.21, 135.59, 132.79, 129.5, 128.3, 125.9, 120.0, 118.6, 70.6, 68.9, 53.0, 43.2, 41.0, 37.3, 37.2, 
35.8, 31.5, 29.9, 26.1, 25.8, 20.7; IR (neat) 1718, 2935 cm-1; HRMS calcd for (M+ +1): 405.2543, 
found 405.2544. 
 
 
(6R,7S,9S,10S,10aS)-6-benzyldecahydro-7,10-methanopyrido[1,2-a]azepin-9-yl 
phenylcarbamate: 1H NMR (400 MHz, CDCl3) δ 7.45 (dd, J = 8.6, 1.0 Hz, 2H), 7.39 – 7.26 (m, 
4H), 7.22 (dd, J = 8.4, 6.3 Hz, 1H), 7.18 – 7.12 (m, 2H), 7.12 – 7.04 (m, 1H), 6.88 (s, 1H), 5.32 – 
5.08 (m, 1H), 3.59 – 3.56 (m, 1H), 3.22 (dd, J = 13.3, 3.0 Hz, 1H), 2.41 (dd, J = 13.2, 10.1 Hz, 
1H), 2.36 – 2.24 (m, 1H), 2.25 – 2.06 (m, 3H), 2.06 – 1.56 (m, 8H), 1.52 – 1.45 (m, 1H), 1.37 
(dd, J = 11.6, 2.4 Hz, 1H), 1.24 (m, 1H): 13C NMR (101 MHz, CDCl3) δ 153.6, 140.1, 138.1, 
129.5, 129.0, 128.3, 125.9, 123.2, 118.5, 70.6, 68.9, 53.0, 43.2, 41.0, 37.3, 37.2, 35.8, 31.6, 29.9, 
26.1, 25.7; IR (neat) 1600, 1702, 2933 cm-1; HRMS calcd for (M+ +1): 391.2387, found 
391.2295. 
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